Hao Liu1, Kari Hemminki, Jan Sundquist. 1. Division of Molecular Genetic Epidemiology, German Cancer Research Centre, Heidelberg, Germany. h.liu@dkfz.de
Abstract
PURPOSE: An increasing incidence and improved prognosis of kidney cancer have led to concern about second primary malignancies. The study of multiple primary malignancies is also important since the association of certain malignancies may guide the search for germline alterations and environmental risk factors. We evaluated bidirectional associations between renal cell carcinoma and other primary cancers. MATERIALS AND METHODS: We studied 8,030 patients with renal cell carcinoma based on the Swedish Family-Cancer Database. The SIR of second cancer was calculated by comparing it to the rate of first cancers. Followup was started in 1993 and continued through 2006. RESULTS: A total of 677 patients had second cancers after the first renal cell carcinoma, including 89 second renal cell carcinomas. In 776 patients renal cell carcinoma was diagnosed after another primary cancer. Histology concordant renal cell carcinoma pairs showed a SIR of 31.04 and 15.15 after clear cell and total renal cell carcinoma, respectively. The highest SIR of 132.46 was noted for synchronous contralateral clear cell renal cell carcinoma. A reciprocally increased risk of renal cell carcinoma was seen after lung, breast, prostate, bladder, thyroid gland, adrenal gland and nervous system cancer as well as after melanoma and nonHodgkin's lymphoma. Clear cell renal cell carcinoma was also in excess after brain hemangioblastoma with a SIR of 70.79. CONCLUSIONS: High risk was found for histology concordant renal cell carcinoma pairs and contralateral renal cell carcinoma. Bidirectional associations of renal cell carcinoma with many other cancers may imply etiological sharing. von Hippel-Lindau syndrome may explain the excess of renal cell carcinoma after brain hemangioblastoma.
PURPOSE: An increasing incidence and improved prognosis of kidney cancer have led to concern about second primary malignancies. The study of multiple primary malignancies is also important since the association of certain malignancies may guide the search for germline alterations and environmental risk factors. We evaluated bidirectional associations between renal cell carcinoma and other primary cancers. MATERIALS AND METHODS: We studied 8,030 patients with renal cell carcinoma based on the Swedish Family-Cancer Database. The SIR of second cancer was calculated by comparing it to the rate of first cancers. Followup was started in 1993 and continued through 2006. RESULTS: A total of 677 patients had second cancers after the first renal cell carcinoma, including 89 second renal cell carcinomas. In 776 patientsrenal cell carcinoma was diagnosed after another primary cancer. Histology concordant renal cell carcinoma pairs showed a SIR of 31.04 and 15.15 after clear cell and total renal cell carcinoma, respectively. The highest SIR of 132.46 was noted for synchronous contralateral clear cell renal cell carcinoma. A reciprocally increased risk of renal cell carcinoma was seen after lung, breast, prostate, bladder, thyroid gland, adrenal gland and nervous system cancer as well as after melanoma and nonHodgkin's lymphoma. Clear cell renal cell carcinoma was also in excess after brain hemangioblastoma with a SIR of 70.79. CONCLUSIONS: High risk was found for histology concordant renal cell carcinoma pairs and contralateral renal cell carcinoma. Bidirectional associations of renal cell carcinoma with many other cancers may imply etiological sharing. von Hippel-Lindau syndrome may explain the excess of renal cell carcinoma after brain hemangioblastoma.
Authors: Barbara Casolla; Serena Candela; Antonio Ciacciarelli; Ludovico Ciolli; Andrea Romano; Michele Acqui; Maria Christina Cox; Giuliano Sette; Francesco Orzi Journal: J Neurol Surg B Skull Base Date: 2018-06-08
Authors: Joanne S Colt; Jonathan N Hofmann; Kendra Schwartz; Wong-Ho Chow; Barry I Graubard; Faith Davis; Julie Ruterbusch; Sonja Berndt; Mark P Purdue Journal: Cancer Causes Control Date: 2017-02-21 Impact factor: 2.506
Authors: Geeta Lal; Megan Groff; James R Howe; Ronald J Weigel; Sonia L Sugg; Charles F Lynch Journal: Ann Surg Oncol Date: 2012-01-07 Impact factor: 5.344
Authors: Mark P Purdue; Lee E Moore; Maria J Merino; Paolo Boffetta; Joanne S Colt; Kendra L Schwartz; Vladimir Bencko; Faith G Davis; Barry I Graubard; Vladimir Janout; Julie J Ruterbusch; Jennifer Beebe-Dimmer; Michele L Cote; Brian Shuch; Dana Mates; Jonathan N Hofmann; Lenka Foretova; Nathaniel Rothman; Neonilia Szeszenia-Dabrowska; Vsevolod Matveev; Sholom Wacholder; David Zaridze; W Marston Linehan; Paul Brennan; Wong-Ho Chow Journal: Int J Cancer Date: 2013-01-15 Impact factor: 7.396
Authors: Sara Karami; Joanne S Colt; Kendra Schwartz; Faith G Davis; Julie J Ruterbusch; Stella S Munuo; Sholom Wacholder; Patricia A Stewart; Barry I Graubard; Nathanial Rothman; Wong-Ho Chow; Mark P Purdue Journal: BMC Cancer Date: 2012-08-08 Impact factor: 4.430
Authors: Tianhui Chen; Mahdi Fallah; Hermann Brenner; Lina Jansen; Elias K Mai; Felipe A Castro; Alexander Katalinic; Katharina Emrich; Bernd Holleczek; Karla Geiss; Andrea Eberle; Kristina Sundquist; Kari Hemminki Journal: Sci Rep Date: 2016-02-24 Impact factor: 4.379
Authors: Jae Young Joung; Whi-An Kwon; Jiwon Lim; Chang-Mo Oh; Kyu-Won Jung; Sung Han Kim; Ho Kyung Seo; Weon Seo Park; Jinsoo Chung; Kang Hyun Lee; Young-Joo Won Journal: Cancer Res Treat Date: 2017-04-19 Impact factor: 4.679